Vaccine. 2007 Apr 20;25(16):3075-9. Epub 2007 Jan 22.

Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand.

Oster P, O'Hallahan J, Aaberge I, Tilman S, Ypma E, Martin D.

Source

Novartis Vaccines and Diagnostics S.r.l., Via Fiorentina 1, 53100 Siena, Italy. philipp.oster@novartis.com

Abstract

To control the devastating group B meningococcal epidemic in New Zealand a strain-specific OMV vaccine (MeNZB) was extensively tested before vaccination of >1,000,000 people under 20 years. After the three-dose course 75% of 6-8-month-old infants and 16-24-month-old toddlers showed four-fold increases in bactericidal antibodies. In 6-10-week-old infants a fourth dose was needed to obtain similar results. After primary vaccination, the antibody titre decline was most pronounced among the youngest but both young infants and toddlers showed a clear booster response to a fourth dose. MeNZB was safe and well tolerated. The comprehensive post-licensure safety surveillance revealed no safety concerns.

Comment in

Vaccine. 2007 Sep 28;25(39-40):6835; author reply 6835-6.

PMID:: 17289223; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Research Support, Non-U.S. Gov't

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Meningococcal Infections - MedlinePlus Health Information

Supplemental Content

Save items

Related citations in PubMed

Re: Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5 year olds in New Zealand, Oster P, O'Hallahan J, Aaberge I, Tilman S, Ypma E, Martin D. Vaccine 2007;25(16):3075-9. [Vaccine. 2007]
Re: Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5 year olds in New Zealand, Oster P, O'Hallahan J, Aaberge I, Tilman S, Ypma E, Martin D. Vaccine 2007;25(16):3075-9.
Lennon D. Vaccine. 2007 Sep 28; 25(39-40):6835; author reply 6835-6. Epub 2007 Jun 19.
New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months. [Pediatr Infect Dis J. 2007]
New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months.
Wong S, Lennon D, Jackson C, Stewart J, Reid S, Crengle S, Tilman S, Aaberge I, O'Hallahan J, Oster P, et al. Pediatr Infect Dis J. 2007 Apr; 26(4):345-50.
MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. [Vaccine. 2005]
MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain.
Oster P, Lennon D, O'Hallahan J, Mulholland K, Reid S, Martin D. Vaccine. 2005 Mar 18; 23(17-18):2191-6.
Review Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand. [Clin Infect Dis. 2009]
Review Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand.
Lennon D, Jackson C, Wong S, Horsfall M, Stewart J, Reid S. Clin Infect Dis. 2009 Aug 15; 49(4):597-605.
Review MeNZB vaccine and epidemic control: when do you stop vaccinating? [Vaccine. 2008]
Review MeNZB vaccine and epidemic control: when do you stop vaccinating?
Loring BJ, Turner N, Petousis-Harris H. Vaccine. 2008 Nov 5; 26(47):5899-904. Epub 2008 Sep 17.

See reviews... See all...

Cited by 6 PubMed Central articles

Population coverage analysis of T-Cell epitopes of Neisseria meningitidis serogroup B from Iron acquisition proteins for vaccine design. [Bioinformation. 2011]
Population coverage analysis of T-Cell epitopes of Neisseria meningitidis serogroup B from Iron acquisition proteins for vaccine design.
Misra N, Panda PK, Shah K, Sukla LB, Chaubey P. Bioinformation. 2011; 6(7):255-61. Epub 2011 Jun 23.
Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and Neisserial heparin binding antigen. [Vaccine. 2011]
Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and Neisserial heparin binding antigen.
Vu DM, Wong TT, Granoff DM. Vaccine. 2011 Feb 24; 29(10):1968-73. Epub 2011 Jan 15.
Vaccine preventability of meningococcal clone, Greater Aachen Region, Germany. [Emerg Infect Dis. 2010]
Vaccine preventability of meningococcal clone, Greater Aachen Region, Germany.
Elias J, Schouls LM, van de Pol I, Keijzers WC, Martin DR, Glennie A, Oster P, Frosch M, Vogel U, van der Ende A. Emerg Infect Dis. 2010 Mar; 16(3):465-72.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to und...
Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand.
Vaccine. 2007 Apr 20 ;25(16):3075-9. Epub 2007 Jan 22 .

PubMed
Conditional gene targeting in the mouse nervous system: Insights into brain func...
Conditional gene targeting in the mouse nervous system: Insights into brain function and diseases.
Pharmacol Ther. 2007 Mar ;113(3):619-34. Epub 2007 Jan 10 .

PubMed
Probiotics during the first 7 years of life: a cumulative risk reduction of ecze...
Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo-controlled trial.
J Allergy Clin Immunol. 2007 Apr ;119(4):1019-21. Epub 2007 Feb 7 .

PubMed
A mathematical model of breast cancer development, local treatment and recurrenc...
A mathematical model of breast cancer development, local treatment and recurrence.
J Theor Biol. 2007 May 21 ;246(2):245-59. Epub 2006 Dec 12 .

PubMed
Crystal structure of the Anabaena sensory rhodopsin transducer.
Crystal structure of the Anabaena sensory rhodopsin transducer.
J Mol Biol. 2007 Mar 30 ;367(3):741-51. Epub 2006 Dec 1 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: